Arcus Biosciences, Inc.
RCUS
$10.53
$0.050.48%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 262.00M | 141.00M | 258.00M | 263.00M | 247.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 262.00M | 141.00M | 258.00M | 263.00M | 247.00M |
| Cost of Revenue | 485.00M | 461.00M | 448.00M | 440.00M | 399.00M |
| Gross Profit | -223.00M | -320.00M | -190.00M | -177.00M | -152.00M |
| SG&A Expenses | 115.00M | 116.00M | 120.00M | 121.00M | 121.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 600.00M | 577.00M | 568.00M | 561.00M | 520.00M |
| Operating Income | -338.00M | -436.00M | -310.00M | -298.00M | -273.00M |
| Income Before Tax | -297.00M | -390.00M | -282.00M | -269.00M | -246.00M |
| Income Tax Expenses | 1.00M | 1.00M | 1.00M | 1.00M | 3.00M |
| Earnings from Continuing Operations | -298.00 | -391.00 | -283.00 | -270.00 | -249.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -298.00M | -391.00M | -283.00M | -270.00M | -249.00M |
| EBIT | -338.00M | -436.00M | -310.00M | -298.00M | -273.00M |
| EBITDA | -328.00M | -426.00M | -300.00M | -288.00M | -264.00M |
| EPS Basic | -4.31 | -4.19 | -3.10 | -3.15 | -3.10 |
| Normalized Basic EPS | -1.97 | -2.61 | -1.79 | -1.82 | -1.77 |
| EPS Diluted | -4.31 | -4.19 | -3.10 | -3.15 | -3.10 |
| Normalized Diluted EPS | -1.97 | -2.61 | -1.79 | -1.82 | -1.77 |
| Average Basic Shares Outstanding | 387.60M | 372.60M | 360.40M | 343.70M | 326.90M |
| Average Diluted Shares Outstanding | 388.00M | 372.60M | 360.40M | 343.70M | 326.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |